scispace - formally typeset
N

Nagahiro Saijo

Researcher at AstraZeneca

Publications -  386
Citations -  31129

Nagahiro Saijo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 65, co-authored 386 publications receiving 28187 citations. Previous affiliations of Nagahiro Saijo include Harvard University.

Papers
More filters
Journal Article

Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.

TL;DR: It was concluded that the chemotherapeutic regimens that include PLM are only marginally effective against non-small cell carcinoma of the lung, with relatively frequent pulmonary fibrosis.
Journal ArticleDOI

Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer.

TL;DR: It was shown that local therapy for the locoregional recurrence had no significant impact on postrecurrent survival or distant failure-free survival, and systemic chemotherapy in addition to local therapy may be of benefit in this population.
Journal ArticleDOI

In vivo and in vitro effects of Nocardia rubra cell wall skeleton on natural killer activity in mice.

TL;DR: The in vivo and in vitro effects of Nocardia rubra cell wall skeleton (N-CWS) on natural killer activity of spleen and peritoneal lymphocytes of C57BL/6 mice were studied.
Journal Article

Sister Chromatid Exchanges Induced in Human Lymphocytes by cis-Diamminedichloroplatinum(II)

TL;DR: Pt(II) is a potent inducer of SCE in human lymphocytes in vivo and in vitro, and follow-up study of the long-term survivors who have been treated with this agent for cancer is necessary because of the possible occurrence of secondary neoplasms.